Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 26;10:5386. doi: 10.1038/s41467-019-13001-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Clinical effects for frequent pairs of dominant and secondary mutations. a, b Clinical features for patients with TET2 and/or SRSF2 mutations. Forest plot shows the odds ratios (OR) of MDS vs. MDS/MPN (left side) and high (HR) vs. low-risk (LR) subtypes (right side) for genetic events of (a) single mutation and (b) pairs of mutations, respectively. The significance was determined by Fisher’s exact test; *P < 0.05 (MDS vs. MDS/MPN). Circle and error bars indicate OR and 95% confidence interval. Blue and red dots depict dominant and secondary mutations. c Clinical feature dependence on mutation combinations. Phenotypic features compared are MDS (n = 1583) vs. MDS/MPN (n = 226) on the x-axis, and low- (n = 1043) vs. high-risk (n = 766) groups on the y-axis. The area of each bubble indicates the frequency of mutations identified in 1809 MDS patients. Bubbles colored blue and red showed dominant and secondary mutations, respectively. Arrows indicate mutation sequence/ordering. All pairs of dominant and secondary mutations with significant phenotypic effects are highlighted by filled bubbles connected by arrows.